BioCentury | Apr 15, 2013
Company News

NexMed, Zhongshan Xiaolan Pharmaceutical Factory deal

...three years and has a 70 percent controlling interest in the venture, to be called NexMed...
...for China NEXM's alprostadil cream to treat erectile dysfunction. (NEXM to raise $3 million, B17.) NexMed Inc....
BioCentury | Apr 8, 2013
Company News

Apricus Biosciences, Biocodex, Mist Pharmaceuticals sales and marketing update

...French subsidiaries, including holding company Finesco S.A.S. and sales and marketing companies Scomedica S.A.S. and NexMed...
BioCentury | Mar 25, 2013
Company News

Apricus Biosciences supply/service news

...French subsidiaries, including holding company Finesco S.A.S. and sales and marketing companies Scomedica S.A.S. and NexMed...
...Scomedica subsidiary last July. Later that month, Apricus acquired Portalis S.A.S, which it later renamed NexMed...
BioCentury | Sep 24, 2012
Company News

Apricus Biosciences, Takeda sales and marketing update

...Apricus' NexMed Inc. subsidiary granted Takeda an exclusive license to commercialize Vitaros alprostadil in the U.K. NexMed...
...Apricus' NexMed Inc. subsidiary granted Takeda an exclusive license to commercialize Vitaros alprostadil in the U.K. NexMed...
BioCentury | Feb 10, 2012
Financial News

Apricus adds $20 million

...$5.25. Apricus proposed the offering late Wednesday, when its share price was $4.66. Apricus (formerly NexMed Inc....
BioCentury | Feb 9, 2012
Financial News

Array, Apricus planning follow-ons

...ARRY-797 , a P38 mitogen-activated protein (MAP) kinase inhibitor in development for pain. Apricus (formerly NexMed Inc....
BioCentury | Jul 11, 2011
Company News

Apricus Biosciences, BioTox Sciences deal

...Apricus (formerly known as NexMed Inc. ) sold its Bio-Quant Inc. subsidiary to CRO BioTox for $5...
...on BioTox's projected revenues. Bio-Quant is a drug discovery and preclinical development CRO. Apricus retains NexMed-related...
BioCentury | Jan 3, 2011
Company News

Apricus Biosciences, Bracco S.p.A. sales and marketing update

...Apricus (formerly NexMed Inc. ) granted Bracco exclusive rights to commercialize and market Vitaros alprostadil in Italy...
BioCentury | Nov 22, 2010
Clinical News

Vitaros alprostadil regulatory update

...topical prostaglandin E1 (PGE1) cream is formulated with NexACT transdermal delivery technology from Apricus (formerly NexMed Inc....
BioCentury | Nov 16, 2010
Company News

Canada approves Vitaros for ED

...topical prostaglandin E1 (PGE1) cream is formulated with Apricus' NexACT transdermal delivery technology. Apricus (formerly NexMed Inc....
Items per page:
1 - 10 of 148
BioCentury | Apr 15, 2013
Company News

NexMed, Zhongshan Xiaolan Pharmaceutical Factory deal

...three years and has a 70 percent controlling interest in the venture, to be called NexMed...
...for China NEXM's alprostadil cream to treat erectile dysfunction. (NEXM to raise $3 million, B17.) NexMed Inc....
BioCentury | Apr 8, 2013
Company News

Apricus Biosciences, Biocodex, Mist Pharmaceuticals sales and marketing update

...French subsidiaries, including holding company Finesco S.A.S. and sales and marketing companies Scomedica S.A.S. and NexMed...
BioCentury | Mar 25, 2013
Company News

Apricus Biosciences supply/service news

...French subsidiaries, including holding company Finesco S.A.S. and sales and marketing companies Scomedica S.A.S. and NexMed...
...Scomedica subsidiary last July. Later that month, Apricus acquired Portalis S.A.S, which it later renamed NexMed...
BioCentury | Sep 24, 2012
Company News

Apricus Biosciences, Takeda sales and marketing update

...Apricus' NexMed Inc. subsidiary granted Takeda an exclusive license to commercialize Vitaros alprostadil in the U.K. NexMed...
...Apricus' NexMed Inc. subsidiary granted Takeda an exclusive license to commercialize Vitaros alprostadil in the U.K. NexMed...
BioCentury | Feb 10, 2012
Financial News

Apricus adds $20 million

...$5.25. Apricus proposed the offering late Wednesday, when its share price was $4.66. Apricus (formerly NexMed Inc....
BioCentury | Feb 9, 2012
Financial News

Array, Apricus planning follow-ons

...ARRY-797 , a P38 mitogen-activated protein (MAP) kinase inhibitor in development for pain. Apricus (formerly NexMed Inc....
BioCentury | Jul 11, 2011
Company News

Apricus Biosciences, BioTox Sciences deal

...Apricus (formerly known as NexMed Inc. ) sold its Bio-Quant Inc. subsidiary to CRO BioTox for $5...
...on BioTox's projected revenues. Bio-Quant is a drug discovery and preclinical development CRO. Apricus retains NexMed-related...
BioCentury | Jan 3, 2011
Company News

Apricus Biosciences, Bracco S.p.A. sales and marketing update

...Apricus (formerly NexMed Inc. ) granted Bracco exclusive rights to commercialize and market Vitaros alprostadil in Italy...
BioCentury | Nov 22, 2010
Clinical News

Vitaros alprostadil regulatory update

...topical prostaglandin E1 (PGE1) cream is formulated with NexACT transdermal delivery technology from Apricus (formerly NexMed Inc....
BioCentury | Nov 16, 2010
Company News

Canada approves Vitaros for ED

...topical prostaglandin E1 (PGE1) cream is formulated with Apricus' NexACT transdermal delivery technology. Apricus (formerly NexMed Inc....
Items per page:
1 - 10 of 148